Your browser doesn't support javascript.
loading
Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.
Kim, Shinhye; Chuang, Erica Sy; Sabaiduc, Suzana; Olsha, Romy; Kaweski, Samantha E; Zelyas, Nathan; Gubbay, Jonathan B; Jassem, Agatha N; Charest, Hugues; De Serres, Gaston; Dickinson, James A; Skowronski, Danuta M.
Afiliação
  • Kim S; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Chuang ES; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Sabaiduc S; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Olsha R; Public Health Ontario, Toronto, Canada.
  • Kaweski SE; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Zelyas N; Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada.
  • Gubbay JB; University of Toronto, Toronto, Canada.
  • Jassem AN; Public Health Ontario, Toronto, Canada.
  • Charest H; University of British Columbia, Vancouver, Canada.
  • De Serres G; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Dickinson JA; Institut national de santé publique du Québec, Québec, Canada.
  • Skowronski DM; Centre Hospitalier Universitaire de Québec, Québec, Canada.
Euro Surveill ; 27(38)2022 09.
Article em En | MEDLINE | ID: mdl-36148674
ABSTRACT
Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI -38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization's decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Euro Surveill Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Euro Surveill Ano de publicação: 2022 Tipo de documento: Article